Only 14.5% of adult patients with moderate or severe asthma are prescribed the recommended SMART combination inhaler regimen ...

While Eli Lilly and Novo Nordisk currently dominate the GLP-1 receptor agonist space, there are more than 50 candidates in ...

Research shows that a new test that assigns a genetic risk score to patients may be able to spot who is likely to be ...

Nestlé is the latest company to join the lucrative world of Ozempic. It’s launching a new line of frozen food created with users of GLP-1 agonist medications in mind.

Persons with asthma or COPD found through community outreach had improvements in lung function and quality of life over 1 year in a randomized trial.

Hims & Hers aims to capitalize on the shortages of the branded drugs Wegovy and Zepbound. Read more to see why I'm bullish on ...

According to AltruBio, the new lead prospect has shown improved potency in down-regulating chronic pathogenic T cells in ...

You've watched others shed pounds in a matter of weeks after taking one of the new blockbuster weight-loss drugs, so y ...

Eli Lilly (NYSE:LLY) has secured China approval for its blockbuster drug tirzepatide for use in treating diabetes.

One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using one, ...

About 4 in 10 people who use GLP-1 agonist drugs do so mainly for weight loss, not to treat diabetes, a new study finds.

Weight loss drugs such as Ozempic and Wegovy are drawing a growing number of lawsuits, as patients accuse the drug ...